The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 607-614

  Sakurai, Toshihiko ^a   Bilim, Vladimir N ^a   Ugolkov, Andrey V ^b   Yuuki, Kaori ^a   Tsukigi, Masaaki ^a   Motoyama, Teiichi ^a   Tomita, Yoshihiko ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Enhancer of zeste homolog 2; MicroRNA 101; Renal cell carcinoma

Indexed keywords

MICRORNA 101; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84862284030     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.035     Document Type: Article

References (30)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2012, 62:10.
2. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997, 80:1198-1220.
3. Bukowski R.M. Cytokine therapy for metastatic renal cell carcinoma. Seminars in Urology Oncology 2001, 19:148-154.
4. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology 2002, 20:289-296.
5. Bukowski R.M. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Expert Opinion on Pharmacotherapy 2010, 11:2351-2362.
6. Yuasa T., Tsuchiya N., Urakami S., Horikawa Y., Narita S., Inoue T., Saito M., Yamamoto S., Yonese J., Fukui I., Nakano K., Takahashi S., Hatake K., Habuchi T. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU International 2011, 105:1811-1813.
7. Di Fiore F., Rigal O., Menager C., Michel P., Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. British Journal of Cancer 2012, 109:1349-1354.
8. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2008, 647:21.
9. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes & Development 2006, 20:1123-1136.
10. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G.A.B., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624.
11. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clinical Cancer Research 2005, 11:8570-8576.
12. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G.A.B., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences 2003, 100:11606-11611.
13. Fluge O., Gravdal K., Carlsen E., Vonen B., Kjellevold K., Refsum S., Lilleng R., Eide T.J., Halvorsen T.B., Tveit K.M., Otte A.P., Akslen L.A., Dahl O. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer 2009, 101:1282.
14. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clinical Cancer Research 2008, 14:6790-6796.
15. Wagener N., Macher-Goeppinger S., Pritsch M., Husing J., Hoppe-Seyler K., Schirmacher P., Pfitzenmaier J., Haferkamp A., Hoppe-Seyler F., Hohenfellner M. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010, 10:524.
16. Hinz S., Weikert S., Magheli A., Hoffmann M., Engers R., Miller K., Kempkensteffen C. Expression profile of the polycomb group protein enhancer of zeste homologue 2 and its prognostic relevance in renal cell carcinoma. The Journal of Urology 2009, 182:2920.
17. Tsukigi M., Bilim V., Yuuki K., Ugolkov A., Naito S., Nagaoka A., Kato T., Motoyama T., Tomita Y. Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3beta. Cancer Letters 2012, 315:189-197.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402.
19. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. British Journal of Cancer 2012, 106:243.
20. Varambally S., Cao Q., Mani R.-S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., Brenner J.C., Yu J., Kim J.H., Han B., Tan P., Kumar-Sinha C., Lonigro R.J., Palanisamy N., Maher C.A., Chinnaiyan A.M. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
21. Friedman J.M., Liang G., Liu C.-C., Wolff E.M., Tsai Y.C., Ye W., Zhou X., Jones P.A. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Research 2009, 69:2623-2629.
22. Friedman R.C., Farh K.K.-H., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 2009, 19:92-105.
23. Pillai R.S. MicroRNA function: multiple mechanisms for a tiny RNA?. RNA 2005, 11:1753-1761.
24. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Letters 2008, 266:6.
25. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871.
26. Wagener N., Holland D., Bulkescher J., Crnković-Mertens I., Hoppe-Seyler K., Zentgraf H., Pritsch M., Buse S., Pfitzenmaier J., Haferkamp A., Hohenfellner M., Hoppe-Seyler F. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. International Journal of Cancer 2008, 123:1545-1550.
27. Avissar-Whiting M., Koestler D.C., Houseman E.A., Christensen B.C., Kelsey K.T., Marsit C.J. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma. Epigenetics 2011, 6:703-709.
28. Tomita Y., Nishiyama T., Fujiwara M., Sato S. Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. British Journal of Cancer 1990, 62:354-359.
29. Sasaki D., Imaizumi Y., Hasegawa H., Osaka A., Tsukasaki K., Choi Y.L., Mano H., Marquez V.E., Hayashi T., Yanagihara K., Moriwaki Y., Miyazaki Y., Kamihira S., Yamada Y. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011, 96:712-719.
30. Smits M., Mir S.E., Nilsson R.J.A., van der Stoop P.M., Niers J.M., Marquez V.E., Cloos J., Breakefield X.O., Krichevsky A.M., Noske D.P., Tannous B.A., Würdinger T. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 2011, 6:e16282.